Frontlight ResearchEarly access
CompletedNo phase
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
Key facts
- Who runs it
- ETS Wound Care, LLC
- Where
- Auburn, Cedar Rapids, Corpus Christi, El Paso, Frederick, Homestead, Las Vegas, Los Angeles, O'Fallon, Pomona, Salem, San Francisco, South Miami, Springfield, and Youngstown, United StatesSee the 15 sites
- Trial code
- Status
- Completed
- People taking part
- 148 people enrolled
- Started
- 13 Sept 2022
- Ended
- 17 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mirragen Advanced Wound Matrix
- Fibracol
- Record updated
- 10 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Subjects must be at least 18 years of age or older
- Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus
- At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app
- The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit
- The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus
- The target ulcer must be full thickness on the foot or ankle that does not probe to bone
- Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:; TCOM ≥30 mmHg; ABI between 0.7 and 1.3; PVR: Biphasic; TBI ˃0.6; As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle
- If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
- Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization
- The subject must consent to using the prescribed off-loading method for the duration of the study
- The subject must agree to attend the weekly study visits required by the protocol
- The subject must be willing and able to participate in the informed consent process
Who cannot take part
- A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded
- A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer
- The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC
- A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded
- A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded
- If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded
- A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy
- The topical application of steroids to the ulcer surface within one month of initial screening is not permitted
- A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded
- A potential subject with end stage renal disease requiring dialysis is excluded
- A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded
- If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded
- If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded
- A subject known to have a life expectancy of < 6 months is excluded
- Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence
- Women who are pregnant or considering becoming pregnant within the next 6 months are excluded
Where in United States
- United Wound Healing P.SAuburn, United States
- Mercy Medical CenterCedar Rapids, United States
- Wound CentricsCorpus Christi, United States
- PULSE: Amputation Prevention Center, LLCEl Paso, United States
- Foot and Ankle Specialists of the Mid AtlanticFrederick, United States
- Southernmost Foot and Ankle SpecialistsHomestead, United States
- Wound Care ExpertsLas Vegas, United States
- LA Foot and AnkleLos Angeles, United States
- Gateway Clinical TrialsO'Fallon, United States
- Casa ColinaPomona, United States
- Foot and Ankle Specialists of the Mid-AtlanticSalem, United States
- Center for Clincal ResearchSan Francisco, United States
- Doctor's Research NetworkSouth Miami, United States
- Foot and Ankle Center of IllinoisSpringfield, United States
- Lower Extremity Institute for Research and TherapyYoungstown, United States
About the trial
What the trial wants to find out
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available treatments for diabetic foot wounds.
The 2 groups in the trial
- SOC primary dressing with MIRRAGEN™Treatment being tested
Mirragen Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix to be used per manufacturer instructions for use in conjunction with offloading and additional (outer) dressing application with moisture retention dressing.
Treatment: Mirragen Advanced Wound Matrix
- SOC primary dressing with FIBRACOL™Existing treatment, for comparison
A commercially available wound dressing to be used per manufacturer's instructions for use in conjunction with offloading and additional (outer) dressing application with moisture retention dressing.
Treatment: Fibracol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Clinical Trial Evaluating the Efficacy of a Borate-based Bioactive Glass Advanced Wound Matrix and Standard of Care Versus Standard of Care Alone
- Record updated
- 10 November 2025